A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge cancer care closer to patients in ...

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

CAR-T cell therapy, which involves genetically engineered T-lymphocytes targeting cancer cells, has shown high efficacy in blood cancers and is being explored for solid tumors and autoimmune diseases.

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it. After treatment with CAR-T ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase 1/2 study. Patients received their CAR-T within 8 to 12 days of lymphodepletion.

CAR T-cell therapies offer high response rates but face logistical challenges, including lengthy "brain-to-vein" times and high costs, limiting their accessibility. Bispecific therapies are more ...